PD-L1 Inhibitor
Immune Checkpoint Inhibitors + Axitinib for Kidney Cancer
Recruiting1 awardPhase 2
Knoxville, Tennessee
This trial is testing a new drug combination for patients with advanced kidney cancer that can't be removed by surgery. The treatment aims to stop the cancer by blocking its blood supply and boosting the immune system. The combination of atezolizumab and bevacizumab has shown promise in treating advanced kidney cancer by helping patients live longer without the disease worsening.
Popular Filters
Trials for Kidney Cancer Patients
PARP Inhibitor
Olaparib for Kidney Cancer
Recruiting1 awardPhase 2
Baltimore, Maryland
This trial is testing the effects of olaparib on metastatic renal cell carcinoma that has a mutation in BAP-1, ATM, BRCA1, BRCA2, PALB2, CHEK2, BRIP1, RAD51C, BARD1, CDK12, CHEK1, FANCL, PP2R2A, RAD51B, RAD51D, or RAD54L. The trial is open-label, meaning that both the doctors and participants know what treatment is being given. This trial is for people who have had prior treatment with at least one immune checkpoint
Tyrosine Kinase Inhibitor
Pembrolizumab + Cabozantinib for Kidney Cancer
Recruiting1 awardPhase 1 & 2
Aurora, Colorado
This trial tests a combination of two drugs, pembrolizumab and cabozantinib, in patients with advanced kidney cancer. Pembrolizumab boosts the immune system to fight cancer, and cabozantinib stops cancer cells from growing. The goal is to find the best dose and see how well the combination works. Cabozantinib was approved for the treatment of advanced kidney cancer after other treatments.
Checkpoint Inhibitor
Nivolumab + Cabozantinib for Kidney Cancer
Recruiting2 awardsPhase 3
Daphne, Alabama
This trial will test whether a combination of nivolumab and cabozantinib is safe and effective in treating people with previously untreated advanced or metastatic renal cell carcinoma, compared to sunitinib.
Radiation
SABR for Kidney Cancer
Recruiting1 awardPhase 2
Dallas, Texas
This trial is testing whether a certain kind of radiation can help extend the amount of time patients with a certain kind of kidney cancer live without their disease getting worse, and whether it can delay the need for systemic therapy.
Trials for Kidney Cell Carcinoma Patients
PARP Inhibitor
Olaparib for Kidney Cancer
Recruiting1 awardPhase 2
Baltimore, Maryland
This trial is testing the effects of olaparib on metastatic renal cell carcinoma that has a mutation in BAP-1, ATM, BRCA1, BRCA2, PALB2, CHEK2, BRIP1, RAD51C, BARD1, CDK12, CHEK1, FANCL, PP2R2A, RAD51B, RAD51D, or RAD54L. The trial is open-label, meaning that both the doctors and participants know what treatment is being given. This trial is for people who have had prior treatment with at least one immune checkpoint
Tyrosine Kinase Inhibitor
Pembrolizumab + Cabozantinib for Kidney Cancer
Recruiting1 awardPhase 1 & 2
Aurora, Colorado
This trial tests a combination of two drugs, pembrolizumab and cabozantinib, in patients with advanced kidney cancer. Pembrolizumab boosts the immune system to fight cancer, and cabozantinib stops cancer cells from growing. The goal is to find the best dose and see how well the combination works. Cabozantinib was approved for the treatment of advanced kidney cancer after other treatments.
Checkpoint Inhibitor
Nivolumab + Cabozantinib for Kidney Cancer
Recruiting2 awardsPhase 3
Daphne, Alabama
This trial will test whether a combination of nivolumab and cabozantinib is safe and effective in treating people with previously untreated advanced or metastatic renal cell carcinoma, compared to sunitinib.
Radiation
SABR for Kidney Cancer
Recruiting1 awardPhase 2
Dallas, Texas
This trial is testing whether a certain kind of radiation can help extend the amount of time patients with a certain kind of kidney cancer live without their disease getting worse, and whether it can delay the need for systemic therapy.
Trials With No Placebo
PARP Inhibitor
Olaparib for Kidney Cancer
Recruiting1 awardPhase 2
Baltimore, Maryland
This trial is testing the effects of olaparib on metastatic renal cell carcinoma that has a mutation in BAP-1, ATM, BRCA1, BRCA2, PALB2, CHEK2, BRIP1, RAD51C, BARD1, CDK12, CHEK1, FANCL, PP2R2A, RAD51B, RAD51D, or RAD54L. The trial is open-label, meaning that both the doctors and participants know what treatment is being given. This trial is for people who have had prior treatment with at least one immune checkpoint
Tyrosine Kinase Inhibitor
Pembrolizumab + Cabozantinib for Kidney Cancer
Recruiting1 awardPhase 1 & 2
Aurora, Colorado
This trial tests a combination of two drugs, pembrolizumab and cabozantinib, in patients with advanced kidney cancer. Pembrolizumab boosts the immune system to fight cancer, and cabozantinib stops cancer cells from growing. The goal is to find the best dose and see how well the combination works. Cabozantinib was approved for the treatment of advanced kidney cancer after other treatments.
Checkpoint Inhibitor
Nivolumab + Cabozantinib for Kidney Cancer
Recruiting2 awardsPhase 3
Daphne, Alabama
This trial will test whether a combination of nivolumab and cabozantinib is safe and effective in treating people with previously untreated advanced or metastatic renal cell carcinoma, compared to sunitinib.
Radiation
SABR for Kidney Cancer
Recruiting1 awardPhase 2
Dallas, Texas
This trial is testing whether a certain kind of radiation can help extend the amount of time patients with a certain kind of kidney cancer live without their disease getting worse, and whether it can delay the need for systemic therapy.
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.